According to a research report from CLSA, looking ahead to 2026, HYGEIA HEALTH's (06078) key growth drivers are expected to include expanding revenue from non-National Reimbursement Drug List sources, enhancing utilization rates at existing hospitals, and reducing its debt ratio to drive operating leverage and rebuild profit margins. The brokerage maintained its "Outperform" rating on HYGEIA HEALTH but lowered its target price from HK$17 to HK$15.9. Despite the company issuing a profit warning, the report believes the earnings decline has largely bottomed out. Specifically, second-half revenue is projected to fall 2% year-on-year to approximately RMB 2 billion, while non-IFRS adjusted net profit is expected to resume positive growth of 3%, indicating improving profit resilience; the stabilization of adjusted net profit is seen as a positive signal of enhanced operational execution.